LAKES COMMUNITY CENTER 

WHERE NATURE IS YOUR NEIGHBOR

Important Dates

Saturday - May 22

Trash Day @ LCC 9:00am

Thursday - June 3

Community Center Meeting @LCC 7:00pm

Saturday - June 5

Town Council @LCC 8:30am

Saturday - May 22

Trash Day @ LCC 9:00am

Thursday - June 3

Community Center Meeting @LCC 7:00pm

Saturday - June 5

Town Council @LCC 8:30am

Thursday - June 10

49er Committee Mtg. @LCC 7:00pm

Saturday- June 12

Chipping Day @LCC 9:00am - noon

SAFETY INFO
Check here for recent information on road closures, fires and weather updates.

In ways that wheat can be a flawlessly crafted Frankengrain that nearly appears to be it was created to exert maximum health harm in the most desirable, irresistible form possible.’.. Children with rheumatoid arthritis may encounter relief by heading gluten-free: study A silent epidemic known as juvenile rheumatoid arthritis , which is now believed to afflict nearly 300,000 children under the age of 18, may be the result of undiagnosed gluten sensitivity or even celiac disease in a few kids, suggests a little-known study published in the Saudi Journal of Gastroenterology . Experts from King Faisal Specialist Hospital and Research Center in Saudi Arabia found that children with JRA who also display indications of CD may experience dramatic improvements after starting a gluten-free diet plan.You will see the complete Kaiser Daily Health Plan Report, search the archives, or join email delivery of in-depth coverage of wellness policy developments, discussions and debates. The Kaiser Daily Health Policy Report is released for Kaisernetwork.org, a free assistance of The Henry J. Kaiser Family Foundation. Copyright 2007 Advisory Table Kaiser and Company Family members Foundation. All rights reserved.

Cetuximab fails in second-line combination for recurrent NSCLC By Joanna Lyford, Senior medwireNews Reporter Outcomes from a stage III trial indicate that cetuximab shouldn’t be given alongside chemotherapy in patients with recurrent non-small-cell lung cancers after platinum-based therapy. In the open-label randomized trial, combination therapy with cetuximab and pemetrexed didn’t improve survival weighed against pemetrexed alone, but was connected with greater toxicity significantly, including loss of life.